Therapeutic potential and recent progression of BTK inhibitors against rheumatoid arthritis.

Autor: Paliwal S; Department of Pharmaceutical Chemistry, DPSRU, New Delhi, India., Bawa S; Department of Pharmaceutical Chemistry, SPER, Jamia Hamdard, New Delhi, India., Shalmali N; Department of Pharmaceutical Chemistry, SPER, Jamia Hamdard, New Delhi, India.; Dr. K. N. Modi Institute of Pharmaceutical Education and Research, Ghaziabad, Uttar Pradesh, India., Tonk RK; Department of Pharmaceutical Chemistry, DPSRU, New Delhi, India.
Jazyk: angličtina
Zdroj: Chemical biology & drug design [Chem Biol Drug Des] 2024 Jul; Vol. 104 (1), pp. e14582.
DOI: 10.1111/cbdd.14582
Abstrakt: Rheumatoid arthritis (RA) is a complex chronic inflammatory illness that affects the entire physiology of human body. It has become one of the top causes of disability worldwide. The development and progression of RA involves a complex interplay between an individual's genetic background and various environmental factors. In order to effectively manage RA, a multidisciplinary approach is required, as this disease is complicated and its pathophysiological mechanism is not fully understood yet. In majority of arthritis patients, the presence of abnormal B cells and autoantibodies, primarily anti-citrullinated peptide antibodies and rheumatoid factor affects the progression of RA. Therefore, drugs targeting B cells have now become a hot topic in the treatment of RA which is quite evident from the recent trends seen in the discovery of various B cell receptors (BCRs) targeting agents. Bruton's tyrosine kinase (BTK) is one of these recent targets which play a role in the upstream phase of BCR signalling. BTK is an important enzyme that regulates the survival, proliferation, activation and differentiation of B-lineage cells by preventing BCR activation, FC-receptor signalling and osteoclast development. Several BTK inhibitors have been found to be effective against RA during the in vitro and in vivo studies conducted using diverse animal models. This review focuses on BTK inhibition mechanism and its possible impact on immune-mediated disease, along with the types of RA currently being investigated, preclinical and clinical studies and future prospective.
(© 2024 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: